Announcements Trials
Browse Landscape

Phase

Phase 1 11Phase 2 6Phase 1/2 4Phase 3 2

Status

Completed 3Terminated 2Not yet recruiting 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

CNS 2Sarcoma 1NET 1Genitourinary 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Sarcoma 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Neoplasm Metastasis 1Melanoma 1Glioma 1Glioblastoma 1Castration Resistant Prostate Cancer 1

Interventions

Cisplatin 1514Carboplatin 1416Cyclophosphamide 1359Gemcitabine 1235Bevacizumab 1223Paclitaxel 1210Radiotherapy 1173Docetaxel 1079pembrolizumab 1026Oxaliplatin 934Capecitabine 898Fluorouracil 832Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 665Etoposide 660Irinotecan 622Leucovorin 574Pemetrexed 508Drug Therapy 491Cetuximab 481Trastuzumab 467Cytarabine 466Magnetic Resonance Spectroscopy 457Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 407Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × TH 302 × Clear all
NCT06836726 2026-01-28

EVO

University Health Network, Toronto

Phase 2 Not yet recruiting
35 enrolled
Genitourinary

Castration Resistant Prostate Cancer

NCT01864538 2025-05-11

A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma

ImmunoGenesis

Phase 2 Terminated
11 enrolled 8 charts
Dermatologic

Melanoma, Neoplasm Metastasis

NCT02402062 2020-07-27

A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
17 enrolled 55 charts
EndocrineGastrointestinalNET

Pancreatic Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT02342379 2020-04-10

TH-302 in Combination With Bevacizumab for Glioblastoma

The University of Texas Health Science Center at San Antonio

Phase 2 Completed
35 enrolled 6 charts
CNS

Glioblastoma

NCT01403610 2019-07-24

Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab

The University of Texas Health Science Center at San Antonio

Phase 2 Completed
28 enrolled 9 charts
CNS

Glioma

NCT02255110 2018-12-14

A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

Merck KGaA, Darmstadt, Germany

Phase 2 Terminated
6 enrolled 6 charts
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡